2017-02-013 - ThermoFlashot - ThermoShot/FlashShot: a New Technology against Antimicrobial Resistant and Biofilm Infections
Acronim & Gínjol codes
ThermoFlashot
2017-02-013
Main technology offer
Combination of two technologies. a thermotherapy nanoantibiotic plus in situ HOCl. The two technologies can kill in vitro effectively and quickly high concetracions of highly resistant bacteries like P.aeruginosa, K.pneumoniae and One.baumanii and biofilms of Pseudomonas.
Ownership
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Market Data
Intubation is a major risk factor associated to ventilator-associated pneumonia (VAP) in patients admitted to the ICU, with an incidence from 2-16 episodes per 1,000 days of mechanical ventilation and an associated mortality that ranges from 3-17%. The endotracheal tubes used for intubation are made of polyvinyl chloride, a thermoplastic that can act as a reservoir for pathogens by providing a surface to which they can adhere and form biofilms. Biofilms develop rapidly after intubation with antibiotic-tolerant structures that can be detected within 24 hours, being one of the most important variables in the pathogenesis of VAP. To date, there is no strategy to prevent or treat these biofilm-associated infections in endotracheal tubes.
14000000000000
0
0
Spin-off creation to which to license the HEATSHOT technology, once pre-clinical pre-regulatory development is completed.
Hospitals and medical centers (public and private) equipped with critical units where patients are on assisted ventilation.
Technology Status
Disruptive breakthrough in comparison to the previous asset (Flashshot) due to its simpler and more elegant operating principle, based exclusively on the effect of hot air introduced into patients. This will imply greater technological feasibility and a more favorable regulatory pathway.
FlashShot: PCT/IB2017/000193 - 02/03/2017 - Abandoned Thermoshot: Australia 2017225481 (abandoned), Brasil BR1120180674850 (abandoned), Canada 3,016,012 (abandoned), Europe EP3423098 (abandoned), Japan 2018-546547 (abandoned), USA 16,078,836 (abandoned)
Additional information
Patents: WO2017149381A1 ; WO2017149378A1 - Date: Sep 8th, 2017 Status: Granted URL: https://patents.google.com/patent/WO2017149381A1/en ; https://patents.google.com/patent/WO2017149378A1/en
These technologies may involve cost savings for public Health Systems in Health-Acquired Infections, estimated in €7 billion per year in EU